Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromo-willardiine is a synthetic analog of willardiine and belongs to the class of L-alpha-amino acids. It is characterized by a bromine atom at the 5-position of the uracil ring. Bromo-willardiine acts as a partial agonist at ionotropic glutamate receptors—specifically AMPA and kainate receptors—in the central nervous system. By binding to these receptors, it induces excitatory synaptic transmission via depolarization of neurons. The compound has been used extensively in neuropharmacological research to study receptor function and desensitization mechanisms. It is not approved for medical use and is primarily utilized as an experimental tool in neuroscience and peptide chemistry[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromo-willardiine.